Showing results (651-660 of 1,340) with videos related to

Sort By:
Pageof 134
Neuro-Oncology Advances|June 23, 2026
A phase 1 trial of iron metabolism-targeting oral gallium maltolate in recurrent and refractory glioblastomaJennifer M Connelly, Casey J Zoss, Aniko Szabo, et al.
Neuro-Oncology Advances|June 24, 2026
Chemotherapy neurotoxicity and aging: Uncovering shared central nervous system pathologies and potential interventionsMaria Sacconi Nunez, Erin M Gibson
Neuro-Oncology Advances|July 24, 2026
A phase 0 clinical trial to evaluate the neuropharmacological profile of posaconazole for glioblastomaAlireza Mansouri, Leonardo de Macedo Filho, Emily Tufano, et al.
Neuro-Oncology Advances|July 24, 2026
Population-based validation of the RANO categories for extent of resection in glioblastomaClaes Johnstad, Ingerid Reinertsen, David Bouget, et al.
Neuro-Oncology Advances|July 23, 2026
Multi-threshold volumetric 18F-FET PET for tumor detection and prognosis in primary gliomaThura Tun Oo, Shaun D Grega, Nathaniel J Smith, et al.
Neuro-Oncology Advances|July 22, 2026
Differential modulation of glioma metabolism and the tumor microenvironment following dexamethasone and bevacizumab treatmentLouise Maise, Felix Krautwurst, Surender Surender, et al.
Neuro-Oncology Advances|August 4, 2026
Targeting replication stress in glioblastoma: From genotoxic treatment and inhibitors of the DNA damage response to immunotherapyAlexandros Pailas, Ana Catarina Vales de Almeida, Miriam Torres-Fernández, et al.
Neuro-Oncology Advances|July 23, 2026
Integrating chemotherapy, radiotherapy, and O6-methylguanine-DNA methyltransferase (MGMT) status with deep-learning cellular tumor volumetry sharpens prediction of glioblastoma recurrence on postoperative MRITaha Belbadaoui, Andrew Forester, Farzad Khalvati, et al.
Neuro-Oncology Advances|August 22, 2026
Tumor treating fields plus temozolomide maintenance after radiochemotherapy in Chinese grade 4 gliomas: Efficacy and predictive biomarkersWenjun Zhu, Jie Rao, Guangyuan Hu, et al.
Neuro-Oncology Advances|August 22, 2026
Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromasHari Sankaran, Eva Dombi, Brittany Glassberg, et al.
Pageof 134